scholarly journals Editorial Comment to Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives

2019 ◽  
Vol 26 (5) ◽  
pp. 542-543
Author(s):  
Katsunori Tatsugami
Keyword(s):  
Renal Cell Carcinoma ◽  
Editorial Comment ◽  
Cell Carcinoma ◽  
Systemic Therapy ◽  
Renal Cell ◽  
Locally Advanced ◽  
Advanced Renal Cell Carcinoma ◽  
Future Perspectives ◽  
Current State

scholarly journals Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives

2019 ◽  
Vol 26 (5) ◽  
pp. 532-542 ◽  
Author(s):  
Sean W Berquist ◽  
Kendrick Yim ◽  
Stephen T Ryan ◽  
Sunil H Patel ◽  
Ahmed Eldefrawy ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Systemic Therapy ◽  
Renal Cell ◽  
Locally Advanced ◽  
Advanced Renal Cell Carcinoma ◽  
Future Perspectives ◽  
Current State

scholarly journals Safety and oncological outcomes for large (stage ≥T2b) and locally advanced renal cell carcinoma: comparison between laparoscopic and modified hand-assisted laparoscopic radical nephrectomy

2020 ◽  
Vol 48 (10) ◽  
pp. 030006052096123
Author(s):  
Xudong Guo ◽  
Hanbo Wang ◽  
Yuzhu Xiang ◽  
Xunbo Jin ◽  
Shaobo Jiang
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Radical Nephrectomy ◽  
Locally Advanced ◽  
Survival Rates ◽  
Renal Tumors ◽  
Advanced Renal Cell Carcinoma ◽  
Operative Duration ◽  
Laparoscopic Radical Nephrectomy

Objective To compare the operative and oncologic outcomes between hand-assisted laparoscopic radical nephrectomy (HALRN) and laparoscopic radical nephrectomy (LRN) for large (stage ≥T2b) and locally advanced renal cell carcinoma. Methods We retrospectively collected data from patients who underwent HALRN or LRN for stage ≥T2b renal cell carcinoma from January 2011 to January 2018 in our institution. The patients’ demographics, perioperative parameters, and postoperative follow-up data were compared between the two groups. The survival outcome was estimated using the Kaplan–Meier method. Results The HALRN group comprised 78 patients, and the LRN group comprised 63 patients. The median operative duration was significantly shorter in the HALRN than LRN group. The two groups were equivalent in terms of the incision length, blood loss, complication rate, and duration of hospitalization. In the HALRN and LRN groups, the 5-year overall survival rates were 69.4% and 73.1%, the 5-year cancer-specific survival rates were 80.0% and 83.3%, and the 5-year progression-free survival rates were 66.4% and 74.7%, respectively, with no significant differences. Conclusions Compared with LRN, HALRN may offer a shorter operative duration and equivalent surgical outcomes without sacrificing oncological efficacy. In addition, HALRN has specific advantages for extremely large and complicated renal tumors.

scholarly journals Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma

2013 ◽  
Vol 3 (1) ◽  
pp. 73 ◽  
Author(s):  
Wassim Kassouf ◽  
Robert Siemens ◽  
Christopher Morash ◽  
Louis Lacombe ◽  
Michael Jewett ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Partial Nephrectomy ◽  
Renal Cell ◽  
Locally Advanced ◽  
Advanced Renal Cell Carcinoma

Subcutaneous Interleukin-2 in the Treatment of Renal Cell Carcinoma. Preliminary Report

1993 ◽  
Vol 60 (4) ◽  
pp. 305-306
Author(s):  
S. Benvenuti ◽  
E. Gastaldi ◽  
B. Mennini ◽  
M. Iacoviello ◽  
M. Caviguone ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Adverse Effects ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Preliminary Report ◽  
Locally Advanced ◽  
Interleukin 2 ◽  
Advanced Renal Cell Carcinoma

10 patients with locally advanced renal cell carcinoma and 5 patients with metastatic renal cell carcinoma were treated with IL-2 subcutaneously. Adverse effects were not important. This study shows that IL-2 alone given subcutaneously is an effective and well-tolerated treatment for renal cell carcinoma.

Sign in / Sign up

Export Citation Format

Share Document